title: Treatment selection and experience in multiple sclerosis: survey of neurologists.
abstract: BACKGROUND
  Multiple sclerosis (MS) is a complex disease with many therapeutic options. Little is known about how neurologists select particular disease-modifying therapies (DMTs) for their patients.
  
  
  OBJECTIVE
  To understand how neurologists make decisions regarding the prescription of DMTs for patients with MS, and to explore neurologists' experiences with individual DMTs.
  
  
  METHODS
  From December 2012 to January 2013, members of a nationwide physician market research panel were sent an online study invitation with a link to a survey website. Eligible neurologists were included if they currently practice medicine in the United States, and if they treat ≥20 patients with MS.
  
  
  RESULTS
  A total of 102 neurologists (n=63 general neurologists; n=39 MS specialists; 81.4% male) completed the survey. The mean (standard deviation) number of years in practice since completing medical training was 16.4 (8.6) years. Overall, the most commonly prescribed DMTs were subcutaneous interferon (IFN) β-1a and glatiramer acetate; approximately 5.5% of patients were untreated. The most important attributes of DMT medication selection were (in order of importance) efficacy, safety, tolerability, patient preference, and convenience. The DMT with the highest neurologist-reported percentage of patients who were "Very/Extremely Satisfied" with their therapy was fingolimod (31.0%), followed by glatiramer acetate (13.9%; P=0.017). Compared with fingolimod (94.0%), significantly fewer (P<0.05) neurologists reported that "All/Most" of their patients were adherent to treatment with glatiramer acetate (78.0%), subcutaneous IFN β-1a (84.0%), and IFN β-1b (75.0%); no significant differences were observed with intramuscular IFN β-1a (92.9%; P=0.75). Patients' calls to neurologists' offices were most commonly related to side effects for all self-injectable DMTs, whereas calls about fingolimod primarily involved insurance coverage issues.
  
  
  CONCLUSIONS
  Our survey results showed that very few patients with MS did not received any DMT. Among the DMTs available at the time of the survey, neurologists reported that patients were most satisfied with, and adherent to, fingolimod, but these patients also faced more problems with insurance coverage when compared with those taking self-injectable DMTs.
authors.affiliation: UBC: An Express Scripts Company, Dorval, QC, Canada.
authors.forename: Kristin A
authors.initials: KA
authors.lastname: Hanson
authors.affiliation: Novartis Pharmaceuticals Corporation East Hanover, NJ, USA.
authors.forename: Neetu
authors.initials: N
authors.lastname: Agashivala
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: Kathleen W
authors.initials: KW
authors.lastname: Wyrwich
authors.affiliation: Novartis Pharmaceuticals Corporation East Hanover, NJ, USA.
authors.forename: Karina
authors.initials: K
authors.lastname: Raimundo
authors.affiliation: Novartis Pharmaceuticals Corporation East Hanover, NJ, USA.
authors.forename: Edward
authors.initials: E
authors.lastname: Kim
authors.affiliation: Hope MS Center, Knoxville, TN, USA.
authors.forename: David W
authors.initials: DW
authors.lastname: Brandes
keywords: disease-modifying therapy; multiple sclerosis; physician survey; treatment adherence; treatment satisfaction; treatment selection
references.citation: Mult Scler. 2012 Jul;18(7):932-46
references.pmid: 22249762
references.citation: Neurology. 2002 Jan 22;58(2):169-78
references.pmid: 11805241
references.citation: BMC Neurol. 2013 Oct 04;13:138
references.pmid: 24093542
references.citation: PLoS One. 2014 Feb 06;9(2):e88472
references.pmid: 24516663
references.citation: Curr Med Res Opin. 2007 Jun;23(6):1209-15
references.pmid: 17559722
references.citation: Patient Prefer Adherence. 2011 Feb 27;5:101-8
references.pmid: 21448467
references.citation: J Manag Care Pharm. 2012 Jan-Feb;18(1):54-62
references.pmid: 22235955
references.citation: Arch Neurol. 2006 Apr;63(4):611-4
references.pmid: 16606780
references.citation: Clin Drug Investig. 2010;30(2):89-100
references.pmid: 20067327
references.citation: Adv Ther. 2011 Jan;28(1):51-61
references.pmid: 21153000
references.citation: Am J Manag Care. 2012 Aug;18(8):460-4
references.pmid: 22928761
references.citation: Arch Neurol. 2006 Apr;63(4):619
references.pmid: 16606782
references.citation: J Neurol. 2009 Apr;256(4):568-76
references.pmid: 19444532
references.citation: Am J Manag Care. 2013 Feb;19(2 Suppl):S15-20
references.pmid: 23544716
references.citation: Curr Med Res Opin. 2013 Dec;29(12):1647-56
references.pmid: 24059944